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A B S T R A C T
While human chorionic gonadotropin (hCG) appears to have an essential role in early pregnancy, it is con-
troversial whether the hyperglycosylated form of hCG (hCG-h), which is the major hCG isoform during the first
4–5 weeks of pregnancy, is able to activate LH/hCG receptor (LHCGR). To address this, we utilized different
extensively characterized hCG and hCGβ reference reagents, cell culture- and urine-derived hCG-h preparations,
and an in vitro reporter system for LHCGR activation. The WHO hCG reference reagent (99/688) was found to
activate LHCGR with an EC50-value of 3.3 ± 0.6 pmol/L (n= 9). All three studied hCG-h preparations were also
able to activate LHCGR, but with a lower potency (EC50-values between 7.1 ± 0.5 and 14 ± 3 pmol/L,
n= 5–11, for all P < 0.05 as compared to the hCG reference). The activities of commercial urinary hCG
(Pregnyl) and recombinant hCG (Ovitrelle) preparations were intermediate between those of the hCG reference
and the hCG-h. These results strongly suggest that the hCG-h is functionally similar to hCG, although it has lower
potency for LHCGR activation. Whether this explains the reduced proportion of hCG-h to hCG reported in pa-
tients developing early onset pre-eclampsia or those having early pregnancy loss remains to be determined.
1. Introduction
The glycoprotein hormones luteinizing hormone (LH), follicle-sti-
mulating hormone (FSH), thyroid stimulating hormone (TSH) and
human chorionic gonadotropin (hCG)1 are heterodimers consisting of a
non-covalently linked common α-subunit (hCGα) and different β-sub-
units determining their biological activity (Pierce and Parsons, 1981).
While TSH and FSH have specific receptors, hCG and LH signal through
a common LH/hCG receptor (LHCGR), which is highly expressed in
ovaries and testes, but also at low levels in some other tissues, like
breast and uterus (reviewed in Ascoli et al., 2002). Ligand binding to a
Gαs protein-coupled LHCGR activates the cAMP system and
subsequently cAMP-dependent protein kinases, but some other sig-
naling routes have also been reported (reviewed in Ascoli et al., 2002).
The major function of hCG is to maintain progesterone production in
the corpus luteum, essential for pregnancy.
In addition to the intact hCG heterodimer, the free β-subunit of hCG
(hCGβ), which is produced especially in non-trophoblastic tumors
(Stenman et al., 2004), has been proposed to be bioactive (Cole and
Butler, 2012), although it does not activate the LHCGR (Catt et al.,
1973; Ryan et al., 1988). We have recently shown that both hCG and
hCGβ stimulate trophoblast invasion independent of the LHCGR (Lee
et al., 2013). Especially in urine, which is often used as a source for
purification of hCG and hCGβ, part of the hCGβ occurs as a
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proteolytically processed, or nicked, isoform (hCGβn) in which the
peptide chain is cleaved between Gly47 and Val48, and less often be-
tween amino acids 43–44, 44–45 and 75–76 (Bidart et al., 1988;
Puisieux et al., 1990; Elliott et al., 1997). hCGβn fragments are con-
nected by disulfide bridges and are able to form a heterodimer (hCGn)
with α-subunit, but this dimer has a very low or no activity at the
LHCGR (Sakakibara et al., 1990). hCGβ can be further processed in the
kidneys to a hCGβ core fragment (hCGβcf), which, in addition to
lacking several amino acids in the region 41–54, is also devoid of the
five N-terminal amino acids as well as amino acids 93–145 forming the
C-terminal peptide (CTP). hCGβcf is unable to form a dimer with hCGα
(Birken et al., 1988; Nisula et al., 1989). Plasma contains very low le-
vels of hCGn and hCGβcf (Hoermann et al., 1994; Alfthan et al., 1992).
Invasive cytotrophoblasts and several cancers, especially tropho-
blastic and testicular cancer, produce hyperglycosylated hCG (hCG-h)
(Ryan et al., 1988; Valmu et al., 2006; Kovalevskaya et al., 1999,
2002a; Stenman et al., 2011; Lempiäinen et al., 2012). hCG-h is char-
acterized by large glycan moieties and defined as hCG detected by a
monoclonal antibody B152 that recognizes a core-2 glycan attached to
Ser-132 of hCGβ and surrounding peptide structures (Valmu et al.,
2006; Birken et al., 1999, 2003a). hCG-h is the major form of hCG
found in serum during the first 4–5 weeks of pregnancy (Kovalevskaya
et al., 1999; Stenman et al., 2011). Specific determination of hCG-h is
clinically useful for cancer diagnostics and prognosis, but also for pre-
diction of pregnancy complications (reviewed in Stenman et al., 2004;
Stenman et al., 2006; Stenman and Alfthan, 2013), e.g., during the first
trimester of pregnancy, a reduced proportion of hCG-h to hCG predicts
early onset pre-eclampsia (Keikkala et al., 2013). In cancer diagnostics,
hCG-h may be especially useful for detection of non-seminomatous
germ cell tumors of the testis, where elevated concentrations also in-
dicate adverse prognosis (Lempiäinen et al., 2012).
It has been suggested that hCG-h is functionally different from non-
hyperglycosylated hCG (Cole, 2010; Fournier et al., 2015). Such sug-
gested activities include stimulation of trophoblast and cancer cell in-
vasion, and activation of the TGFβ-receptor (Cole and Butler, 2012;
Handschuh et al., 2007; Evans et al., 2015; Berndt et al., 2013). How-
ever, in our studies on highly purified and well characterized hCG and
hCGβ preparations, with different degrees of hyperglycosylation, we
have not seen any clear glycosylation-related modulation of pro-in-
vasive activity of hCG/hCG-h (Lee et al., 2013). Furthermore, activation
of the TGFβ-receptor may be due to TGFβ-contamination in the hCG-h
preparations used (Koistinen et al., 2015). Thus, it remains con-
troversial whether hyperglycosylation of hCG has specific (patho)phy-
siological significance or is just a consequence of the altered glycosy-
lation in cancer and trophoblast cells of early pregnancy. While the
activation of LHCGR by hCG is well established, studies on the activity
of hCG-h on LHCGR activation have given discordant results (Berndt
et al., 2013; Crochet et al., 2012; Mazina et al., 2015a), ranging from
inactivity to somewhat reduced activity. This may be due to differences
between various hCG preparations used and their poor characteriza-
tion, but also the assays used. To address these contradictory findings,
we studied LHCGR activation by several extensively characterized hCG
preparations and report that hCG-h is able to activate the LHCGR, al-
though with lower potency than hCG.
2. Materials and methods
2.1. hCG, hCGβ and their hyperglycosylated forms
WHO international reference preparations for hCG (code 99/688),
nicked hCG (99/642), hCGβ (99/650) and nicked hCGβ (99/692) were
obtained from National Institute for Biological Standards and Control
(NIBSC, Potters Bar, Hertfordshire, UK). Recombinant hCG (Ovitrelle)
and urinary hCG (Pregnyl) were purchased from Merck Serono Europe
(Darmstadt, Germany). hCG-h from early pregnancy (pregnancy week
5) and a patient with testicular cancer were purified from urine by
several chromatography steps, including a Sepharose column coupled
with B152 antibody, as previously reported (Valmu et al., 2006). In-
formed consent was obtained from all individuals whose urine samples
were used for purification of hCG-isoforms and the use of the samples
have been approved by the institutional ethics committee at Helsinki
University Hospital. Glycans of these hCG-h preparations and sig-
nificant enrichment of hyperglycosylated hCG, as defined by the pre-
sence of core-2 type O-glycan attached to Ser-132, upon B152 pur-
ification have been described previously (Valmu et al., 2006). hCG-h
from conditioned culture media (day 12) of human embryonic stem
cells (hESC line H9; WiCell Research Institute, Madison, WI) differ-
entiated into trophoblast-like cells with FGF2 inhibition and BMP4
activation (Koel et al., 2017) was purified with B152 antibody affinity
chromatography. The hCG concentrations (including hCG-h) were de-
termined by a commercial immunofluorometric assay (PerkinElmer,
Turku, Finland), and hCGβ, hCGβcf and hyperglycosylated forms of
hCG and hCGβ by specific in-house immunoassays calibrated against
WHO standards, except for hCG-h assay, which was calibrated with
human choriocarcinoma JEG-3 cell derived hCG (Lee et al., 2013;
Alfthan et al., 1992; Stenman et al., 2011; Lempiäinen et al., 2008). The
limit of detection of all assays was< 2 pmol/L and the intra-assay
coefficient of variation< 10% at concentrations above 10 pmol/L.
2.2. Western immunoblotting
hCG or hCGβ (15–80 nmol/L) were denatured by boiling in
NuPAGE® LDS Sample Buffer (Life Technologies, Carlsbad, CA) to which
2.4% β-mercaptoethanol and 13mmol/L dithiothreitol (DTT) were
added. Samples of 20 μl were loaded onto SDS-polyacrylamide gel
(NuPAGE® Novex® 4–12% Bis-Tris Gel, Life Technologies). After elec-
trophoresis in MES buffer (Life Technologies) the proteins were trans-
ferred to polyvinylidene difluoride membranes, blocked overnight at
4 °C with 1% BSA in 50mmol/L Tris-buffered saline (TBS), pH 7.7, and
with 3% milk powder in TBS at room temperature for one hour. The
primary antibody against hCGβ (A0231, DAKO, Glostrup, Denmark) in
3% milk powder in TBS was incubated with the membrane for two
hours at room temperature. After washing with TBS containing 0.1%
Tween, the membrane was incubated with peroxidase-conjugated anti-
rabbit IgG (711-035-152, Jackson ImmunoResearch Laboratories, Ely,
UK) for one hour at room temperature. After washing, detection was
performed with ECL solution (32209, Thermo Fisher Scientific,
Rockford, IL).
2.3. LHCGR activation assay
For monitoring LHCGR activation we used Madin-Darby Canine
Kidney (MDCK) cells stably expressing human LHCGR and quantified
receptor-triggered changes in cyclic adenosine monophosphate (cAMP)
levels by a Förster resonance energy transfer (FRET) biosensor (Mazina
et al., 2015a, 2015b, 2017). This method allows highly sensitive de-
tection of LHCGR activation, with the limit of detection (LoD) and limit
of quantitation (LoQ) for hCG being 0.96 pmol/L and 2.9 pmol/L, re-
spectively.
The biosensor expression vector mTurq2Δ_Epac(CD,ΔDEP)_td
cp173Ven (H188) (Klarenbeek et al., 2015) was kindly provided by Dr.
Kees Jalink from the Netherlands Cancer Institute, and modified to be
used in BacMam system as previously described (Mazina et al., 2015a,
2015b, 2017). Briefly, the pcDNA3.1+ expression vector with the H188
gene was cloned into the pFastBac™ 1 vector, and the polyhedrin pro-
moter from the pFastBac™ 1 vector was replaced with the powerful
mammalian cytomegalovirus promoter. The resulting construct was
used to produce bacmid DNA, which was subsequently transfected into
Spodoptera frugiperda Sf9 insect cells to obtain the BacMam virus. The
virus was amplified, and the stocks stored at −80 °C. The viral titers
were determined experimentally by a cell size-based assay using Sf9
cells (Mazina et al., 2015b). The mammalian MDCK cell line used for
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the measurements was a kind gift from Dr Prema Narayan (Southern
Illinois University); the initial cell line had been obtained from ATCC
(Manassas, VA) (catalog number CRL 2935). The LHCGR-expressing
MDCK cells were grown as adherent monolayers at 37 °C and 5% CO2 in
a humidified incubator in Dulbecco's Modified Eagle's Medium and
Ham's F-12 nutrient mixture supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, 0.1mg/mL streptomycin and 0.25 μg/mL
amphotericin B.
The assay protocol was adopted from Mazina and coworkers
(Mazina et al., 2015a, 2015b, 2017), except that LHCGR-expressing
MDCK cells were used instead of COS-7 cells. Briefly, cells were treated
with viral stock (multiplicity of infection: 100–300) in 5mL of growth
medium for 3–4 h at 37 °C in a humidified CO2 incubator. After pre-
incubation with the virus, the medium was aspirated, the cells were
trypsinized and resuspended in fresh growth medium containing 10mM
sodium butyrate (Sigma-Aldrich, St. Louis, MO) for enhanced protein
expression. Next, the cells were seeded onto a transparent 96-well clear-
bottom cell culture plate (BioLite 130188, Thermo Fisher Scientific,
Rochester, NY) at the density of about 45,000 cells per well (this
number varied for different experiments). The transduced cells were
cultured for further 21 h at 37 °C for recombinant protein production.
On the day of the assay, the growth medium was replaced with 100 μL
phosphate-buffered saline (PBS) one hour prior to the experiment.
The dilutions of hormones were performed on transparent 96-well
clear-bottom plates (269620, Thermo Fisher Scientific, Denmark) into
PBS containing 7.5 μmol/L BSA to reduce non-specific binding. Low-
binding pipette tips were used and a new pipette tip was taken for every
dilution. The fluorescence intensities were registered prior and after
addition of the hormones using either Synergy™ NEO HTS Multi-Mode
Microplate Reader (BioTek Instruments Inc., Winooski, VT) with filter-
based detection at excitation wavelength of 420/50 nm and simulta-
neous dual emission at 485/20 and 540/25 nm, or PHERAstar plate
reader (BMG LABTECH GmbH, Ortenberg, Germany), with excitation at
427 nm and simultaneous dual emission at 480 and 530 nm. After ad-
dition of hormones, readings were taken every two minutes for













where CFP0 and YFP0 refer to the fluorescence emissions at 480 nm and
530 nm (or 485 and 540 nm) in the given well before and CFP or YFP
after the hormone treatment, respectively.
To establish EC50 for each ligand, ΔFRET values, calculated for data
points taken 60min after the addition of hormones, were plotted
against concentrations of the given ligand. The curves (dose-response
with variable slope) were analyzed using GraphPad Prism 6.0
(GraphPad Software, La Jolla, CA).
To establish LoD and LoQ of the assay, ΔFRET values, calculated for
data points taken 60min after addition of normal hCG (WHO reference
reagent 99/688), were plotted against concentrations of the given li-
gand. Because fluorescence was measured using different instruments
with different gains, normalization of each data set (n=9) was ne-
cessary: the ΔFRET value obtained without hCG was defined as 0%, and
the ΔFRET value obtained for highest concentration hCG was defined as
100%. Next, linear regression was used for fitting of data points re-
presenting 0–2.5 pmol/L hCG using GraphPad Prism 6.0. From the
pooled normalized data, the slope of linear regression (S) and standard
deviation of blank (σ) were calculated. The LoD and LoQ values of the







To establish kinetic parameters for activation of LHCGR pathways
by different hormones, the increase of ΔFRET was plotted against time
after addition of each hormone preparation. For each hormone, one
ΔFRET vs time curve was chosen per individual measurement. To en-
sure maximum quality of data (i.e., representing not too fast kinetics yet
a sufficient measurement window), the chosen curve usually featured
data measured at hormone concentrations above its EC50 value, but not
hormone concentrations giving maximal activation. Each curve was
then fitted to a one-phase association equation using GraphPad Prism
6.0; Y0 value was fixed at 0. The rate constant obtained for each curve
was then divided by the corresponding concentration of ligand; the
average of the pooled data for one ligand yielded the value of the ap-
parent association rate constant konapp. As we had no information on the
concentration of LHCGR in the system, but LHCGR was over-expressed,
we did not compensate konapp values for receptor concentration as-
suming that the latter was equal in all measurements.
In studies exploring absence of binding of hCGβ to LHCGR, trans-
fected cells were incubated for 2 h with 100 μL of PBS or solutions of
hCGβ (99/650) (final concentration of 1800 pmol/L; 7 wells) or hCGβn
(99/692) (1200 pmol/L; 7 wells) in PBS. Measurement of biosensor
signal prior to or following addition of the samples confirmed that no
change in FRET occurred during 2 h incubation with hCGβn. hCGβ
induced a signal, which could be attributed to contamination of the
preparation with a small amount of hCG as detected by an im-
munoassay (Table 1). Next, 10 μL of a dilution series of hCG (99/688)
was added to both of the aforementioned series, and another 2 h
measurement was performed. In the second measurement, EC50 values
were established for hCG (99/688) after preincubation with hCGβ or
hCGβn. The content of hCG in the hCGβ (99/650) sample was taken
into account when calculating EC50 value for hCG (99/688).
3. Results
Since the hCG may exist in many different forms, like nicked hCG,
which is common in hCG preparations isolated from urine and has been
reported to lack LHCGR stimulating activity, we characterized the
preparations used by specific immunoassays for hCG heterodimer, free
hCGβ, hCGβcf and hyperglycosylated hCG/hCGβ (Table 1). The hCG
reference contained about 20% of hyperglycosylated hCG and the hCG-
h preparations were ∼100% hyperglycosylated. Nicked hCG was de-
tected by reducing Western blotting for hCGβ (Fig. 1). While the nicked
hCGβ reference (Fig. 1, lane 8) contained only nicked form, the nicked
hCG reference (lane 4) appeared to contain a significant amount, about
50%, of non-nicked form. Pregnyl (lanes 1 and *) also contained some
nicked hCG/hCGβ. It is noteworthy that recombinant hCG (Ovitrelle,
lane 2) showed an additional lower molecular weight band of hCGβ,
suggesting the presence of a variant form of hCG.
As expected, hCG activated LHCGR with high efficiency, while
hCGβ was devoid of activity or had only residual activity corresponding
to the minor hCG contamination in the samples (Table 1, Fig. 2). The
EC50 value for LHCGR activation by the hCG reference (Table 1, pre-
paration #1) was 3.3 ± 0.6 pmol/L (mean ± SEM, n=9). All hCG-h
preparations (#4, #5 and #6) had lower potency than hCG, the EC50
values varying between 7.1 ± 0.5 and 14 ± 3 pmol/L (P < 0.05 for
all, unpaired t-test with Welch's correction, n=5–11). The maximal
stimulation at high concentrations of hCG (#1–3) and hCG-h (#4–6)
were very similar (P > 0.05 for all hCG-h preparations as compared to
hCG). Nicked hCG (#7) had relatively low activity (24 ± 6 pmol/L,
P < 0.05 as compared to the hCG reference), which was compatible
with the presence of non-nicked intact hCG in the preparation (Table 1,
Fig. 1). The activities of commercial urinary hCG (Pregnyl, #2) and
recombinant hCG (Ovitrelle, #3) were intermediate between those of
the hCG reference and hCG-h preparations (for Ovitrelle, P < 0.05 as
compared to the hCG reference).
The kinetics of LHCGR activation by different hCG preparations was
determined by elucidating the apparent on-rate constants (konapp)
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(Table 1, Fig. 2). Here, we calculated konapp by fitting the obtained
ΔFRET curves to the pseudo-first-order exponential equation and nor-
malization of the measured rate factor by total concentration of the
hormone in the assay. Because the equilibrium EC50 value of a biolo-
gically active compound is proportional to its equilibrium dissociation
constant KD, which in turn can be calculated as the ratio of dissociation
and association rate constants, substances with low EC50 values are
expected to feature slow dissociation and fast association kinetics. The
comparison of konapp values indeed showed that hCG had the most rapid
effect. The effect of hCG-h was slower, and the slowest activation was
triggered by nicked hCG, confirming the trends observed for EC50 va-
lues of different hCG isoforms.
To confirm that hCGβ does not bind to LHCGR, we measured EC50
for hCG reference (99/688) after 2 h pre-incubation of cells with ele-
vated concentrations of hCGβ (99/650) (final concentration 1.8 nmol/
L) or hCGβn (99/692) (1.2 nmol/L) (Fig. 2). In both cases, the EC50
values for hCG reference (99/688) were similar to the EC50 value ob-
tained without pre-incubation with hCGβ or hCGβn (P > 0.05, two-
tailed Student's t-test).
4. Discussion
While hCG appears to have an essential role in early pregnancy, it
has remained controversial whether the hyperglycosylated form of
hCG, i.e., hCG-h, which is the major isoform of hCG secreted by the
placenta during the first 4–5 weeks of pregnancy (Kovalevskaya et al.,
1999, 2002a; Stenman et al., 2011), is able to activate LHCGR (Berndt
et al., 2013; Crochet et al., 2012; Mazina et al., 2015a). We show here,
using highly purified and characterized hCG preparations, that hCG-h
activates LHCGR, although with lower potency than non-hyperglyco-
sylated hCG, suggesting functional similarity of these two hCG-iso-
forms, but also that glycosylation may regulate the activity of hCG
during early pregnancy.
The bioactivity of hCG-isoforms has often been studied using cel-
lular systems of non-human species, in which LHCGR is structurally
somewhat different from the human receptor (Troppmann et al., 2013).
For studies on the differences between hCG-isoforms on LHCGR acti-
vation, it is important to use an assay utilizing human LHCGR, like the
one used in this study. Using this model we showed that all three stu-
died hCG-h preparations had significantly lower potency for LHCGR
activation than the WHO hCG reference, which contained about 20% of
hCG-h, the rest representing non-hyperglycosylated form as detected by
specific immunoassays. The hyperglycosylated preparations included
early pregnancy, testicular cancer and differentiated stem cell-derived
hCG-h, indicating that the lower activity is not limited to a certain hCG-
h preparation. As shown previously (Catt et al., 1973; Ryan et al.,
1988), hCGβ was not able to activate LHCGR. Interestingly, commercial
recombinant hCG (Ovitrelle) showed lower activity than the hCG re-
ference and similar trend was observed also for Pregnyl. This may be
because of the heterogeneity of Pregnyl, i.e., it contained some hCG-h
and nicked hCG, and is known to contain several impurities (Koistinen
et al., 2015; Yarram et al., 2004). Ovitrelle seemed to contain two major
components, which may represent glycosylation variants. This hetero-
geneity in SDS electrophoresis has been described also previously
(Riccetti et al., 2017) and may explain the reduced activity.
The lower potency of hCG-h for LHCGR activation was supported by
our kinetics studies, showing that the effect of hCG-h was slower than
that of hCG. Furthermore, we have previously shown that conditioned
cell culture medium from human choriocarcinoma JEG-3 cells, which
produce hCG-h resembling that from early pregnancy and cancer pa-
tients (Valmu et al., 2006), activates LHCGR (Mazina et al., 2015a).
When this hCG has been enriched from the media by Concanavalin-A
lectin-affinity chromatography, it has been found to be less active than
Table 1
hCG and hCGβ preparations used for LHCGR activation studies.
hCG (sourcea) hCG (%)b hCGβ (%)b hCG(β)-h (%)c hCG(β)n (%)d LHCGR activation,e EC50 (pmol/L) LHCGR activation,e konapp (s−1)
1. hCG (99/688)f 99.6 0.4 20 – 3.3 ± 0.6 (n= 9) (1.2 ± 0.2)× 108 (n= 6)
2. hCG (Pregnyl) 93.9 6.1 14 <10 6.1 ± 1.6 (n= 5) (9.5 ± 1.8)× 107 (n= 3)
3. hCG (Ovitrelle) 99.6 0.4 0.01 – 7.5 ± 1.6 (n = 9)* (8.6 ± 1.6)× 107 (n= 5)
4. hCG-h (TCa) 88.8 11.2 ∼100 – 10 ± 3 (n = 6)* (3.7 ± 1.7)× 107 (n = 3)*
5. hCG-h (PW 5) 87.9 12.1 ∼100 – 14 ± 3 (n = 5)* (3.2 ± 0.9)× 107 (n = 5)**
6. hCG-h (stem cell) 94.9 5.1 ∼100 n.a. 7.1 ± 0.5 (n = 11)*** (6.4 ± 0.6)× 107 (n = 11)*
7. hCGn (99/642)f 94.5 5.5 25 ∼50 24 ± 6 (n = 5)* (2.1 ± 0.8)× 107 (n = 5)***
8. hCGβ (99/650)f,g 0.4 99.6 9.3 – > 1000 (n = 3)*** n.a.
9. hCGβn (99/692)f,g 1.1 98.9 8.9 ∼100 >1000 (n = 3)*** n.a.
a PW, pregnancy week; TCa, non-seminomatous germ cell tumor of testis.
b Percentage of molar amount of intact hCG and free hCGβ in the preparations (these represent both non-hyperglycosylated and hyperglycosylated forms).
c The percentage of hyperglycosylated forms of hCG and hCGβ [hCG(β)-h] is indicative as the assay recognizes hCGβ-h with somewhat lower affinity than hCG-h.
d The amount of nicked hCG(β) [hCG(β)n] is a rough estimate based on Western immunoblotting (Fig. 1). -, undetectable; n.a., not analyzed.
e Activation of LHCGR by different preparations as defined by the concentration needed for half-maximal activation (EC50) and kinetics of the activation (konapp).
Data represents mean ± SEM of 3–11 separate assays (all with three replicates). The concentrations used for LHCGR assay are based on hCG concentration
(preparations #1–7) or in case of hCGβ (preparations #8–9) on hCGβ concentration.* indicates P ≤ 0.05,**P ≤ 0.01 and***P≤0.001 as compared to WHO
international hCG reference reagent (99/688) (i.e., preparation #1). n.a., not analyzed.
f The numbers in parenthesis refer to the NIBSC codes of the preparations.
g < 1.0% of the immunoreactive hCGβ represents core fragment (hCGβcf) form as determined by a specific immunoassay (Alfthan et al., 1992).
Fig. 1. Detection of nicked hCGβ by Western blotting. *, Note that hCG
(Pregnyl) also contained nicked hCG(β), which is well visible only after longer
exposure of the blot with film as shown in the right lane.
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non-hyperglycosylated hCG (Berndt et al., 2013). Contrary to these
results, it has been reported that purified hCG-h is unable to activate
LHCGR, as determined by the lack of induction of progesterone pro-
duction in luteinized granulosa cells stimulated with hCG-h (Crochet
et al., 2012). These earlier discordant results may be explained by
differences between various hCG-h preparations, as many of the studies
have been compromised by poor characterization of the preparations
used. Especially nicking of the hCG, which is common in hCG isoforms
isolated from urine (Bidart et al., 1988; Puisieux et al., 1990; Elliott
et al., 1997; Cole et al., 1993), compromises interpretation of the re-
sults. We found that the activity of the nicked hCG reference corre-
sponded and, thus, is likely to be explained by the presence of intact
non-nicked hCG, which has been estimated to represent 10–15%
(Birken et al., 2003b), or even more based on our Western blotting
Fig. 2. Activation of LHCGR by different hCG-isoforms. Representative examples of time- and dose-responses in LHCGR activation assay with (a) hCG reference
preparation (99/688), (b) hCG-h (purified from pregnancy week 5 urine) and (c) the same preparation as in (a) after 2 h preincubation with hCGβn (99/692). The
dotted line indicates 60min time-point for which dose-response curves are shown in (d). For clarity, the graphs for some of the highest doses, shown in panel d, are
not shown in panels a–c. (e) EC50-values for LHCGR activation by different hCG-isoforms and (f) kinetics of the activation. * indicates P ≤ 0.05, **P ≤ 0.01 and
***P≤0.001 as compared to WHO international hCG reference reagent (99/688).”
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results, of total hCG in this preparation.
The only apparent difference between hCG-h and hCG is in their
glycosylation. In theory, this may affect the tertiary structure of hCG/
hCG-h and/or dimer formation with α-subunit, but it is feasible that the
glycan(s) are directly responsible for differences in activation of the
LHCGR. The variation we observed between different hCG-h prepara-
tions may result from variation in glycan structures (Valmu et al.,
2006), typical for glycoproteins (Varki, 2017; Koistinen et al., 2003).
Previously, the signaling of hCG through LHCGR has been found to be
dependent on its glycosylation, e.g., deglycosylated hCG does not in-
duce signaling, although it is able to bind to LHCGR (Sairam, 1989;
Richard et al., 2007). While our results show that hCG-h activates
LHCGR less efficiently than hCG, the used reporter system is not able to
address whether this is due to the steric effects of glycans in hCG-h
decreasing the binding to the receptor or due to decreased signal
transduction after the hormone has bound to its receptor. Noteworthy,
in our experiments excess of hCGβ did not inhibit the response gener-
ated by the hCG reference. This suggests that, unlike deglycosylated
hCG, hCGβ does not bind to the LHCGR as also reported previously
(Catt et al., 1973). Especially, the glycan attached to Asn-52 in hCGα
appears to be important for LHCGR activation (Matzuk et al., 1989), but
the regulation of hCG activity by glycosylation is complex, and thus
other glycans are also likely to play a role. Such a regulation of gly-
coprotein activity for their cognate receptors has been well established
in several systems (Varki, 2017). Interestingly, LH and hCG, both of
which signal through LHCGR, have been found to have somewhat dif-
ferent effects downstream of LHCGR activation, including modulation
of activity of certain protein kinases and gene expression (Casarini
et al., 2012, 2018). Whether hCG and hCG-h are different in this respect
(Arey and López, 2011) remains to be studied.
The lower potency of hCG-h to stimulate LHCGR may have (patho)
physiological consequences during the first few weeks after the im-
plantation, when hCG-h is the major hCG isoform (Kovalevskaya et al.,
1999, 2002a; Stenman et al., 2011). Later on, after 4–5 weeks of
pregnancy, when hCG-h is still the dominant hCG isoform, its levels are
already significantly increased, which may compensate its lower po-
tency in LHCGR activation in corpus luteum and other tissues. This is
supported by our observation that maximal activation of LHCGR was
similar with both hCG and hCG-h, although higher concentrations of
hCG-h were needed for that. During the first weeks of pregnancy, hCG-h
is likely to stimulate trophoblast invasion independently of the LHCGR
activation (Lee et al., 2013), but it may also have LHCGR mediated
function(s), in addition to corpus luteum, also in uterine and other cells
(Ascoli et al., 2002). Interestingly, a recent study reported a woman
with an inactive mutant LHCGR who maintained a normal pregnancy
after becoming pregnant with ovum donation (Mitri et al., 2014). This
suggests that the maintenance of pregnancy through LHCGR activation
is not necessary and that during pregnancy the main hCG effect may be
mediated by other mechanisms than LHCGR activation. Clinical studies
have suggested that low concentrations of hCG-h or low ratio of hCG-h
to hCG already on the day of implantation is associated with pregnancy
loss (Cole, 2012; Sasaki et al., 2008). However, during that time the
levels of hCG-h and hCG are extremely low, making their accurate
detection difficult. Contrary to these finding, in IVF treatments it has
been found that during the first weeks after embryo transfer the pro-
portion of hCG-h to hCG stayed higher in women with early pregnancy
loss, as compared to those with a successful IVF pregnancy
(Kovalevskaya et al., 2002b). Later during the first trimester of the
pregnancy a reduced proportion of hCG-h to hCG has been found to
indicate risk for early onset pre-eclampsia (Keikkala et al., 2013). Al-
though these studies suggest that hCG-h is involved in normal early
pregnancy and perhaps also in early onset pregnancy complications, its
specific role remains to be established. It is important to note, that the
half-life of hCG-h/hCG in circulation and, thereby, the biopotency may
also be affected by differences in glycosylation (Mi et al., 2014). So far,
the half-life of hCG-h is not known.
We have previously shown that when human embryonic stem cells
are differentiated into trophoblast-like cells with FGF2 inhibition and
BMP4 activation they produce hCG-h (Koel et al., 2017), which suggests
that these differentiated cells are similar to early pregnancy cyto-
trophoblast cells (Kovalevskaya et al., 2002a). Here we report that the
hCG-h produced by these differentiated embryonic stem cells is able to
activate LHCGR. Thus, this stem cell model would be suitable for
studying the function(s) of trophoblast derived hCG-h.
In conclusion, we showed here that hyperglycosylated hCG is able to
activate LHCGR, although with lower potency than hCG. This strongly
suggests that the hCG-h is functionally similar to hCG. Whether this
explains the reduced proportion of hCG-h to hCG found in patients
developing early onset pre-eclampsia or those having early pregnancy
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